SC II Acquisition, the second blank check company led by the CEO of Nukkleus, raised $150 million by offering 15 million units at $10. Each unit consists of one share of common stock and one right to receive one-fifth of one share upon the completion of an initial business combination.
SC II Acquisition is led by CEO and Chairman Menachem Shalom, the CEO of Nukkleus (NUKK), which itself went public via SPAC merger in 2023 as a crypto-focused fintech, but has since pivoted to being a defense-focused holding company. He is joined by CFO Asaf Yarkoni, the CFO of both Kamari Pharma and Aroma Republic. Both men also hold the same role at their previous SPAC, defense-focused Kochav Defense Acquisition (KCHVU; +4% from $10 offer price), which raised $220 million in May 2025, and is currently searching for a target.
SC II Acquisition plans to target businesses that are established, with strong free cash flow potential, a competitive advantage, and experienced management teams within growing sectors or cyclical opportunities.
SC II Acquisition plans to list on the Nasdaq under the symbol SCIIU. D. Boral Capital acted as sole bookrunner on the deal.
